Summary: Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT.

Top Publications

  1. Schwartz M, Wellink H, Gooszen H, Conchillo J, Samsom M, Smout A. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut. 2007;56:20-8 pubmed
    ..The effects persisted up to 12 months. However, the reduction in oesophageal acid exposure was not greater after endoscopic treatment than after a sham procedure. ..
  2. Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, et al. The impact of aluminium in acid-suppressing drugs on the immune response of BALB/c mice. Clin Exp Allergy. 2007;37:1566-73 pubmed
    ..This indicates that orally applied sucralfate may lead to an enhanced risk of food allergy not only by inhibiting peptic digestion but also by acting as a Th2 adjuvant. ..
  3. Kwiatek M, Roman S, Fareeduddin A, Pandolfino J, Kahrilas P. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34:59-66 pubmed publisher
    ..By creating a low density gel 'raft' that floats on top of gastric contents, alginate-antacid formulations may neutralise the 'acid pocket'...
  4. Rubino C, Bhavnani S, Ambrose P, Forrest A, Loutit J. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22:279-85 pubmed publisher
    ..single-dose crossover study, the pharmacokinetics (PK) of pirfenidone were investigated with or without food and antacids in healthy adult volunteers...
  5. Rohof W, Bennink R, Smout A, Thomas E, Boeckxstaens G. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2013;11:1585-91; quiz e90 pubmed publisher
    ..These findings indicate the importance of the acid pocket in GERD pathogenesis and establish alginate-antacid as an appropriate therapy for postprandial acid reflux. ..
  6. Lutchman D, Pillay S, Naidoo R, Shangase N, Nayak R, Rughoobeer A. Evaluation of the buffering capacity of powdered cow's, goat's and soy milk and non-prescription antacids in the treatment of non-ulcer dyspepsia. S Afr Med J. 2006;96:57-61 pubmed
    ..The buffering capacities of 25 ml aliquots of each of the powdered milk products, the antacids alone and the combination of antacid and milk were determined...
  7. Van Marrewijk C, Mujakovic S, Fransen G, Numans M, de Wit N, Muris J, et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Lancet. 2009;373:215-25 pubmed publisher
    ..Although treatment success with either step-up or step-down treatment is similar, the step-up strategy is more cost effective at 6 months for initial treatment of patients with new onset dyspeptic symptoms in primary care. ..
  8. Brunner R, Wallmann J, Szalai K, Karagiannis P, Altmeppen H, Riemer A, et al. Aluminium per se and in the anti-acid drug sucralfate promotes sensitization via the oral route. Allergy. 2009;64:890-7 pubmed publisher
    ..This suggests that orally applied SUC leads to an enhanced risk for food allergy, not only by inhibiting peptic digestion but also by acting as a Th2-adjuvant by its ALUM content. ..
  9. Pali Schöll I, Herzog R, Wallmann J, Szalai K, Brunner R, Lukschal A, et al. Antacids and dietary supplements with an influence on the gastric pH increase the risk for food sensitization. Clin Exp Allergy. 2010;40:1091-8 pubmed publisher was to assess the sensitization capacity of the dietary supplement base powder and of over-the-counter antacids. Changes of the pH as well as of protein digestion due to base powder or antacids were measured in vitro...

More Information


  1. Lin M, Lin S, Chan L, Lu Y. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14:806-18 pubmed
    To compare the effects of food and antacids on the bioavailability of first-line anti-tuberculosis drugs...
  2. Tarnawski A, Ahluwalia A, Jones M. Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids. Curr Pharm Des. 2013;19:126-32 pubmed
    ..defense, injury, protection and ulcer healing with a focus on mucosal protective and ulcer healing actions of antacids. The gastric mucosa is continuously exposed to a variety of noxious factors, both endogenous such as: 0...
  3. Kahrilas P, McColl K, Fox M, O Rourke L, Sifrim D, Smout A, et al. The acid pocket: a target for treatment in reflux disease?. Am J Gastroenterol. 2013;108:1058-64 pubmed publisher
  4. Luther J, Higgins P, Schoenfeld P, Moayyedi P, Vakil N, Chey W. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73 pubmed publisher
    ..pylori infection. Both therapies yielded suboptimal eradication rates. Patient compliance and side effects are similar for quadruple and triple therapies. ..
  5. Williams D, Peng B, Bailey C, Wire M, Deng Y, Park J, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31:764-76 pubmed publisher
    ..The aim of these studies was to assess the effect of food and antacids on the pharmacokinetic and safety profiles of eltrombopag...
  6. Shin J, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528-34 pubmed
    ..PPIs with longer half-life promise to improve acid suppression. All PPIs give excellent healing of peptic ulcers and produce good results in reflux esophagitis. PPIs combined with antibiotics eradicate Helicobacter pylori...
  7. Améndola R, Santos M, Massa J, Vazquez H, Smecuol E. Effects of a single low dose of ranitidine and effervescent antacids on intragastric acidity in healthy volunteers. Acta Gastroenterol Latinoam. 2007;37:231-7 pubmed
    ..We suggest that the given combination could be effective, fast and safe for sporadic pyrosis or mild grastroesophageal reflux symptoms. ..
  8. Sweis R, Kaufman E, Anggiansah A, Wong T, Dettmar P, Fried M, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled,. Aliment Pharmacol Ther. 2013;37:1093-102 pubmed publisher
    ..Standard pH-impedance monitoring is suitable for clinical studies of GA in gastro-oesophageal reflux disease patients where proximal reflux is the primary outcome. ..
  9. Untersmayr E, Jensen Jarolim E. The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol. 2008;121:1301-8; quiz 1309-10 pubmed publisher
    ..Thus antiulcer agents impeding gastric protein digestion have a major effect on the sensitization and effector phase of food allergy. ..
  10. Dehlink E, Yen E, Leichtner A, Hait E, Fiebiger E. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. Clin Exp Allergy. 2009;39:246-53 pubmed publisher
    ..51, 95% CI 1.35-1.69), but not for other allergic diseases. These data provide first evidence of a significant association between in utero exposure to acid-suppressive drugs and the risk of developing childhood asthma. ..
  11. Chen T, Chou L, Hwang S. Application of a data-mining technique to analyze coprescription patterns for antacids in Taiwan. Clin Ther. 2003;25:2453-63 pubmed
    Although antacids are popular drugs with a long history of use, their true utilization patterns-including over-the-counter use-have rarely been documented...
  12. Zhu M, Nix D, Adam R, Childs J, Peloquin C. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy. 2001;21:891-7 pubmed
    To determine the effect of a high-fat meal, orange juice, and antacids on absorption of a single oral dose of cycloserine and to estimate its population pharmacokinetic parameters. Randomized, four-period, crossover study...
  13. Peloquin C, Namdar R, Dodge A, Nix D. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis. 1999;3:703-10 pubmed
    To determine the intra- and intersubject variability in and the effects of food or antacids on the pharmacokinetics of isoniazid (INH). Randomized, four-period cross-over Phase I study in 14 healthy male and female volunteers...
  14. Temple M, Nahata M. Comparative palatability of 22 liquid antacids. Aliment Pharmacol Ther. 2000;14:421-5 pubmed
    To compare the palatability, acid neutralizing capability, and costs of different antacids. Volunteers between the ages of 18 and 60 years were given 22 antacids...
  15. Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer. 2001;92:269-75 pubmed
    ..Risk factors statistically associated with delayed diarrhea include advanced age and the use of CPT-11 without OA and CD...
  16. Stass H, Böttcher M, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40 Suppl 1:39-48 pubmed
    ..Absorption of moxifloxacin is impaired by concomitant administration of aluminium- and magnesium-containing antacids and administration of these agents should be staggered...
  17. Hurenkamp G, Grundmeijer H, van der Ende A, Tytgat G, Assendelft W, van der Hulst R. Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study. Aliment Pharmacol Ther. 2001;15:1047-54 pubmed
    ..To evaluate prospectively the effect of H. pylori eradication on the requirement of acid-suppressant drug or antacids and the evolution of dyspeptic symptoms in chronic acid-suppressant drug users with peptic ulcer disease...
  18. Liu J, Chen T, Hwang S. Concomitant prescription of non-steroidal anti-inflammatory drugs and antacids in the outpatient setting of a medical center in taiwan: a prescription database study. Eur J Clin Pharmacol. 2001;57:505-8 pubmed
    Although antacids were ineffective in preventing serious gastrointestinal complications caused by non-steroidal anti-inflammatory drugs (NSAIDs), many physicians in Taiwan still prescribe antacids concomitantly with NSAIDs...
  19. Hurenkamp G, Grundmeyer H, Bindels P, Tytgat G, van der Hulst R. How do primary care physicians use long-term acid suppressant drugs? A population-based analysis of Dutch general practices. J Fam Pract. 2002;51:241-5 pubmed
    ..Patients with ulcer disease may stop taking acid suppressants after apparent successful H pylori eradication. Tapering strategies must be developed for patients with mild reflux disease or functional dyspepsia. ..
  20. Snell P, Oo C, Dorr A, Barrett J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol. 2002;54:372-7 pubmed
    ..p.l.c./MS/MS assay. Pharmacokinetic parameters were calculated for oseltamivir and Ro 64-0802. Since antacids are locally acting drugs and generally not expected to be absorbed substantially into the systemic system, no ..
  21. Untersmayr E, Schöll I, Swoboda I, Beil W, Forster Waldl E, Walter F, et al. Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice. J Allergy Clin Immunol. 2003;112:616-23 pubmed
    ..Approximately 10% of the adult population uses antacids for the treatment of dyspeptic disorders, drugs that hinder peptic digestion...
  22. Peloquin C, Namdar R, Singleton M, Nix D. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115:12-8 pubmed
    Determine the intrasubject and intersubject variability in, and the effects of food or antacids on, the pharmacokinetics of rifampin (RIF). Randomized, four-period crossover phase I study. Fourteen healthy male and female volunteers...
  23. Altschuler E. Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. Med Hypotheses. 1999;53:22-3 pubmed
    ..Aluminum is thought to be a cellular toxin. Here I suggest that aluminum, and in particular aluminum-containing antacids may contribute to the pathogenesis of idiopathic PD.
  24. Moayyedi P, Soo S, Deeks J, Forman D, Harris A, Innes M, et al. Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther. 2003;17:1215-27 pubmed
    Evidence for the effectiveness of antacids, histamine-2 receptor antagonists, bismuth salts, sucralfate and prokinetic therapy in non-ulcer dyspepsia is conflicting...
  25. Redelmeier D, McAlister F, Kandel C, Lu H, Daneman N. Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ. 2010;340:c2608 pubmed publisher
    ..After adjustment for patient and surgical characteristics, acid suppressants are not associated with an increased risk of postoperative pneumonia among elderly patients admitted for elective surgery. ..
  26. Baker G, Fraser R, Young G. Subtypes of functional dyspepsia. World J Gastroenterol. 2006;12:2667-71 pubmed
    ..In conclusion, no classification provides for an adequate treatment-based approach to the syndrome of functional dyspepsia. As a consequence treatment remains largely empiric. ..
  27. Dauer E, Thompson D, Zinsmeister A, Dierkhising R, Harris A, Zais T, et al. Supraesophageal reflux: validation of a symptom questionnaire. Otolaryngol Head Neck Surg. 2006;134:73-80 pubmed
    ..b-2b. ..
  28. Patrick L. Gastroesophageal reflux disease (GERD): a review of conventional and alternative treatments. Altern Med Rev. 2011;16:116-33 pubmed
    ..This article discusses these challenges, investigates the mechanisms of damage in GERD, and explores the existing data on unconventional forms of treatment, including melatonin, acupuncture, botanicals, and dietary interventions...
  29. Jensen A, Callesen T, Hagemo J, Hreinsson K, Lund V, Nordmark J. Scandinavian clinical practice guidelines on general anaesthesia for emergency situations. Acta Anaesthesiol Scand. 2010;54:922-50 pubmed publisher
    ..Outside the operation room, rapid sequence intubation is also considered the safest method. For all patients, precautions to avoid aspiration and other complications must also be considered at the end of anaesthesia. ..
  30. Gisbert J, Castro Fernández M, Bermejo F, Pérez Aisa A, Ducons J, Fernandez Bermejo M, et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol. 2006;101:243-7 pubmed
    ..Levofloxacin-based rescue therapy constitutes an encouraging empirical third-line strategy after multiple previous H. pylori eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, and tetracycline. ..
  31. Izumi M, Morita S, Nishian Y, Miyamoto T, Kasumoto H, Oue M, et al. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films. Ren Fail. 2008;30:952-8 pubmed publisher
  32. Oridate N, Takeda H, Yamamoto J, Asaka M, Mesuda Y, Nishizawa N, et al. Helicobacter pylori seropositivity predicts outcomes of acid suppression therapy for laryngopharyngeal reflux symptoms. Laryngoscope. 2006;116:547-53 pubmed
    ..The laryngopharyngeal, not esophageal, symptom relief by acid-suppression therapy was significantly lower among H. pylori antibody-negative cases than among antibody-positive cases. ..
  33. Holle G. Pathophysiology and modern treatment of ulcer disease. Int J Mol Med. 2010;25:483-91 pubmed
    ..The symptoms of both diseases are also compared with the findings in the normal controls. ..
  34. Rey E, Elola Olaso C, Rodriguez Artalejo F, Locke G, Diaz Rubio M. Use of antisecretory drugs among consumers of non-steroidal anti-inflammatory drugs in the general population. Aliment Pharmacol Ther. 2006;24:1585-92 pubmed
    ..9% vs. 10.7%). Current strategies to prevent GI lesions in NSAID users are not effective from a population perspective, especially in subjects without UGI symptoms. ..
  35. Martin P, Schneck D, Dane A, Warwick M. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24:1231-5 pubmed
    ..coenzyme A (HMG-CoA) reductase inhibitor used for the treatment of dyslipidaemia, may be co-administered with antacids in clinical practice...
  36. Poh C, Navarro Rodriguez T, Fass R. Review: treatment of gastroesophageal reflux disease in the elderly. Am J Med. 2010;123:496-501 pubmed publisher
    ..Overall, proton pump inhibitors seem to be safe for both short- and long-term therapy in elderly patients with GERD. Antireflux surgery may be safe and effective in a subset of elderly patients with GERD. ..
  37. Tsimmerman I, Vologzhanina L. [Gastroesophageal reflux disease: pathogenesis, clinical manifestation, diagnostics, and treatment]. Klin Med (Mosk). 2005;83:16-24 pubmed
  38. Ruggiero A, Arena R, Battista A, Rizzo D, Attinà G, Riccardi R. Azole interactions with multidrug therapy in pediatric oncology. Eur J Clin Pharmacol. 2013;69:1-10 pubmed publisher
    ..The co-administration of azoles and antineoplastic agents, corticosteroids, immunosuppressants, antacids, antiemetics, antiepileptic drugs and analgesics was investigated, and a practical guide on the management of ..
  39. Rodgers C, van Zanten S. A meta-analysis of the success rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol. 2007;21:295-300 pubmed
    ..Both PPI-based triple therapy and quadruple therapy perform well in Canada for the treatment of H pylori infection. ..
  40. Hamdy E. Long-term outcomes of laparoscopic antireflux surgery. Hepatogastroenterology. 2011;58:56-63 pubmed
    ..Younger males, typical reflux symptoms (heartburn without dysphagia) and preoperative response to medication are predictors of superior outcomes. Short floppy complete wrap is more durable than an incomplete one. ..
  41. Chakraborty S, Shukla D, Vuddanda P, Mishra B, Singh S. Effective in-vivo utilization of lipid-based nanoparticles as drug carrier for carvedilol phosphate. J Pharm Pharmacol. 2011;63:774-9 pubmed publisher
  42. Kim D, Kim Y, Cho H, Lee Y. Scrub typhus meningoencephalitis occurring during doxycycline therapy for Orientia tsutsugamushi. Diagn Microbiol Infect Dis. 2011;69:271-4 pubmed publisher
    ..Clinicians should be alerted to the possibility that meningoencephalitis can occur because of inadequate maintenance of serum doxycycline level caused by antacids administered along with doxycycline.
  43. Byrne P, Ravi N, Al Sarraf N, Rowley S, Moran T, Reynolds J. The Rossetti-Nissen fundoplication--effective in managing gastro-oesophageal reflux disease. Surgeon. 2008;6:19-24 pubmed
  44. den Hollander W, Kuipers E. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother. 2012;13:2625-36 pubmed publisher
    ..Primary prevention of NSAID-related gastropathy can be enhanced by better education for clinicians and patients, so that both right prescription of gastroprotective agents as therapy adherence will improve. ..
  45. Filler G, Roach E, Yasin A, Sharma A, Blake P, Yang L. High prevalence of elevated lead levels in pediatric dialysis patients. Pediatr Nephrol. 2012;27:1551-6 pubmed publisher
    ..005 mg/l. We found a high prevalence of elevated Pb levels in pediatric CKD patients that correlated with the calcium carbonate dose and GFR. Lead levels should be monitored in these patients. ..
  46. Fry L, Monkemuller K, Malfertheiner P. Systematic review: endoluminal therapy for gastro-oesophageal reflux disease: evidence from clinical trials. Eur J Gastroenterol Hepatol. 2007;19:1125-39 pubmed
    ..Currently, however, there are not enough scientific and clinical data on safety, efficacy and durability to support the use of endoluminal therapies for GORD in routine clinical practice. ..
  47. Pham C, Regal R, Bostwick T, Knauf K. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006;40:1261-6 pubmed
    ..If all GERDs were acceptable long-term indications, 27% (31 of 115) would have met criteria for acceptable outpatient use. There is considerable excess usage of acid suppressants in both the inpatient and outpatient settings. ..
  48. Sharma P, Chey W, Hunt R, Laine L, Malfertheiner P, Wani S. Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective. Dis Esophagus. 2009;22:461-6 pubmed publisher
    ..Validation of this proposed classification by well-designed prospective multicenter studies is awaited. ..
  49. Sabati A, Kempainen R, Milla C, Ireland M, Schwarzenberg S, Dunitz J, et al. Characteristics of gastroesophageal reflux in adults with cystic fibrosis. J Cyst Fibros. 2010;9:365-70 pubmed publisher
    ..GER symptoms were present in a majority of patients. Females and patients with weight loss require special attention to their GER symptoms. Many patients on acid suppression continued to be report symptoms. ..
  50. Demir M, Göktürk S, Ozturk N, Serin E, Yilmaz U. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients. Digestion. 2010;82:47-53 pubmed publisher
    ..05). The bismuth-based quadruple eradication regimen as first-line therapy is safe, tolerable and achieves a high cure rate in patients with DM, and successful eradication may be beneficial on dyspeptic symptoms. ..
  51. West P, Horowitz B. Delayed recrudescence to toxic salicylate concentrations after salsalate overdose. J Med Toxicol. 2010;6:150-4 pubmed publisher
    ..Recrudescence of salicylate concentrations to a degree that would dictate reinstitution of therapy for overdose is unusual and may warrant prolonged monitoring of serum salicylate concentrations in salsalate ingestions. ..
  52. Sulz M, Manz M, Grob P, Meier R, Drewe J, Beglinger C. Comparison of two antacid preparations on intragastric acidity--a two-centre open randomised cross-over placebo-controlled trial. Digestion. 2007;75:69-73 pubmed
    Rennie and Riopan Gel are 2 of the most well-known and popular over-the-counter antacids; for heartburn symptoms, pain relief is fast with both preparations. A direct comparison with respect to intragastric acidity has not been done yet...
  53. Takeda Y, Tsuduki E, Izumi S, Hojo M, Kamimura M, Naka G, et al. A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. Br J Cancer. 2005;93:1341-9 pubmed
    ..This regimen of irinotecan and cisplatin with ADP resulted in promising efficacy with acceptable toxicity for patients with advanced NSCLC. This regimen is a candidate for the experimental arm towards future phase III studies. ..